Evidence map›Paper›PMID 33585194›Full record

ArticleFrontiers in oncology2020

The Impact of Diabetes Mellitus on the Second Primary Malignancies in Colorectal Cancer Patients.

Jana Halamkova, Tomas Kazda, Lucie Pehalova, Roman Gonec, Sarka Kozakova, Lucia Bohovicova, Ondrej Slaby, Regina Demlova, Marek Svoboda, Igor Kiss

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jana HalamkovaDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czechia.
Tomas KazdaDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia.
Lucie PehalovaInstitute of Health Information and Statistics of the Czech Republic, Prague, Czechia.
Roman GonecDepartment of Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czechia.
Sarka KozakovaDepartment of Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czechia.
Lucia BohovicovaDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czechia.
Ondrej SlabyDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czechia.
Regina DemlovaDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia.
Marek SvobodaDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czechia.
Igor KissDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czechia.
Masaryk Memorial Cancer Institute · CZMasaryk University · CZCentral European Institute of Technology · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAll colorectal cancer (CRC) survivors have an increased risk of developing second primary malignancies (SPMs). The association between diabetes mellitus (DM) and the risk of cancer is well known. However, the role of DM and its therapy in the development of SPMs in CRC patients is not well described.

methodsIn this single-institutional retrospective analysis we identified 1,174 colorectal carcinoma patients, median follow-up 10.1 years, (median age 63 years, 724 men). All patients over 18 years with histologically confirmed CRC who were admitted in the period 1.1. 2003- 31.12.2013 and followed-up till 31.12. 2018 at the Masaryk Memorial Cancer Institute (MMCI) were screened for eligibility. The exclusion criteria were CRC diagnosed at autopsy, lost to follow-up and high risk of development of SPMs due to hereditary cancer syndrome. Tumours are considered multiple primary malignancies if arising in different sites and/or are of a different histology or morphology group. Comparisons of the basic characteristics between the patients with SPM and the patients without SPM were performed as well as comparison of the occurrence of SPMs by the site of diagnosis between the DM and non-DM cohorts and survival analyses.

resultsA SPM was diagnosed in 234 (20%) patients, DM in 183 (15%) patients. DM was diagnosed in 22.6% of those with SPM vs. in 13.8% of those without SPM (p=0.001). The most common types of SPMs in DM patients were other CRC, kidney, lung, bladder and nonmelanoma skin cancer, but only carcinoma of the liver and bile duct tracts was significantly more common than in the group without DM. Although breast cancer was the second most common in the group with DM, its incidence was lower than in the group without DM, as well as prostate cancer. A significantly higher incidence of SPMs was found in older CRC patients (≥ 65 years) and in those with lower stage colon cancer and DM. No significant difference in DM treatment between those with and without a SPM was observed including analysis of type of insulin.

conclusionCRC patients with diabetes mellitus, especially those with older age, and early stages of colon cancer, should be screened for second primary malignancies more often than the standard population. Patients without DM have longer survival. According to the occurrence of the most common second malignancies, a clinical examination, blood count, and ultrasound of the abdomen is appropriate, together with standard breast and colorectal cancer screening, and lung cancer screening under certain conditions, and should be recommended in CRC survivors especially in patients with intercurrent DM, however the necessary frequency of screening remains unclear.

Indexed as

cancer survivorscolorectal cancerdiabetes mellitusmultiple primary neoplasmssecond primary malignanciessecond primary neoplasms

Identifiers

PMID33585194
PMCPMC7878972
OpenAlexW3126890685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.